Study to Evaluate the Safety of CG-P5 Peptide Eye Drops in Patients Diagnosed With Age-related Wet Macular Degeneration

Conditions

• Age-related Wet Macular Degeneration

Eligibility Criteria

Sex

ALL

Age

50 Years - N/A

Healthy Volunteers

Not accepted

Interventions

• CG-P5 peptide — DRUG
  Patient will instill daily 1 package of CG-P5 peptide eye drops in the study eye \[self-administered\] using the single use tear-off disposable packaging
• Placebo — DRUG
  Patient will instill daily 1 package of Placebo eye drops in the study eye \[self-administered\] using the single use tear-off disposable packaging
• Aflibercept Injection [Eylea] — DRUG
  Patient will receiver Eylea® (Aflibercept) intravitreal injection once in a month

Study Details

This will be a randomized, comparative, parallel, clinical study to assess initial safety and tolerability of CG-P5 peptide eye drops compared to placebo in patients diagnosed with age-related wet macular degeneration

Key Dates

Start date

Dec 22, 2023

Status verified

Feb 2025

Primary completion

May 31, 2025

Completion

Aug 31, 2025

Study Design

Enrollment

45 participants (estimated)

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

TREATMENT

Arms

• Experimental: CG-P5 peptide eye drops
• Placebo Comparator: Placebo Eye drops
• Active Comparator: Intravitreal injection of Eylea®

Primary Outcome Measure

The percentage of occurrence of Adverse Events (AE) [ Time Frame: Screening, Day 0, Day 28, Day 56 & Day 84 ]

Central Contacts

• Ishita Trivedi
  +1- 609-594-6709
  [email protected]
• Eldho Jose
  [email protected]

Locations (7)

Find similar trials in Manchester, CT